Trials / Completed
CompletedNCT03825718
A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 2 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is an early, open, single-centered trial.
Detailed description
The aim of this study is to evaluate the safety and tolerance of GC007F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 20 subjects to receive GC007F therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC007F | GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg. |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2020-09-01
- Completion
- 2020-12-01
- First posted
- 2019-01-31
- Last updated
- 2022-04-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03825718. Inclusion in this directory is not an endorsement.